International Legal Approaches to the Issue of Admissibility of the Use of Genomic Technologies in Medicine

Author:

Gazina N. I.1ORCID

Affiliation:

1. Kutafin Moscow State Law University (MSAL)

Abstract

The purpose of the paper is to determine the main international standards and positions of international intergovernmental and non-governmental organizations regarding the use of genomic technologies in medicine, which are reflected in their documents. At the universal level, there is no international treaty containing uniform rules in this area, but there are many documents of international organizations (such as WHO, UNESCO) that set out the relevant standards. At the regional level, the experience of the Council of Europe in the field of legal regulation of genomic medicine plays a significant role. National approaches to the legal regulation of genomic medicine vary. In such conditions, the practice of international non-governmental organizations in the field of biomedicine and genetic technologies plays a significant role. They set standards and represent the positions of the biomedical community.Based on the analysis of international acts, it can be concluded that the general position of the international biomedical community is that genome editing technologies can be widely used for therapeutic and scientific purposes, provided that there is no criterion for transmitting genes to descendants. Genome editing should be carried out in accordance with international professional and ethical standards, including the principles of benefit over harm and informed consent. Discussions about the admissibility of hereditary genome editing continue. The prevailing approach of international organizations is that there are currently no reasonable standards for the safety and effectiveness of this technology, while research itself is encouraged.

Publisher

Kutafin Moscow State Law University

Reference7 articles.

1. Aktualnye problemy sovremennogo mezhdunarodnogo prava: materialy ezhegodnoy mezhvuzovskoy nauchno-prakticheskoy konferentsii, g. Moskva, 8–9 aprelya 2011 g: v 2 ch. / otv. red. A. Kh. Abashidze, E. V. Kiseleva. — Ch. II. — M., 2012. — 508 s.

2. Andorno R. Principles of International Biolaw. Bruylant, 2013. — URL: https://www.academia.edu/4063596/Principles_of_international_biolaw (data obrashcheniya: 20.05.2023).

3. Wert G. de, Pennings G., Clarke A. et al. Human germline gene editing: Recommendations of ESHG and ESHRE // European Journal of Human Genetics 26. 2018. — P. 445–449. — URL: https://doi.org/10.1038/s41431-017-0076-0.

4. Isasi R., Kleiderman E., Knoppers B. M. Genetic technology regulation. Editing policy to fit the genome? // Science. — 2016. — DOI: 10.1126/science.aad6778. PMID: 26797999.

5. Kolata G., Wee S.-L., Belluck P. Chinese Scientist Claims to Use Crispr to Make First Genetically Edited Babies // The New York Times. — November 26, 2018. — URL: https://www.nytimes.com/2018/11/26/health/geneediting-babies-china.html (data obrashcheniya: 20.09.2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3